Aurinia eye drug falls short in improving tolerability versus Restasis, but beats on efficacy
Allergan’s best-selling dry eye drug Restasis was developed after the immunosuppressant was originally shown to enhance tear production in dogs. Similarly, Canada’s Aurinia Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.